<ref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="B117"><label>117</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Voci</surname><given-names>D</given-names></name><name><surname>Gotschi</surname><given-names>A</given-names></name><name><surname>Held</surname><given-names>U</given-names></name><name><surname>Bingisser</surname><given-names>R</given-names></name><name><surname>Colucci</surname><given-names>G</given-names></name><name><surname>Duerschmied</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial</article-title>. <source>Thromb Res</source>. (<year>2023</year>) <volume>221</volume>:<page-range>157&#8211;63</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.thromres.2022.10.021</pub-id>, PMID: <?supplied-pmid 36396519?><pub-id pub-id-type="pmid">36396519</pub-id>
</mixed-citation></ref>